US 11,685,766 B2Granted

14-3-3 targeting peptides for cancer treatment

AssigneesCreighton University, NUtech Ventures

InventorsLaura Hansen, Sandor Lovas, Nicholas Palermo

Life of this patent

Estimating the term…

Loading patent…

Abstract

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Ac-Gln-Arg-Gln-Asn-Ser-(PO32−)-Ala-Pro-Ala-Arg-NH2 (SEQ ID NO: 4) and a second targeting peptide comprising a structure of Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32−)-Trp-Ala-Gly-NH2 (SEQ ID NO: 5), and a third targeting peptide comprising a modification of or a substituted derivative of the peptide of SEQ ID NO: 4 or SEQ ID NO: 5.

Claims5

Dependent claims

A peptide composition, the peptide composition having a peptide consisting of the formula:

X—R1—R2—R3—R4-Ser-(PO32−)—R5-Pro-R6-Arg-Y, wherein
X represents hydrogen, acetyl or propionyl group,
R1 represents an L or D-amino acid residue selected from the group consisting of:
Gln, Trp, Tyr, Phe, His,
R2 represents an L or D-amino acid residue selected from the group consisting of:
Arg, Lys, Orn,
R3 represents an L or D-amino acid residue selected from the group consisting of:
Gln, Arg, Lys, Orn, Pro, Trp, Tyr, Phe, His,
R4 represents an L or D-amino acid residue selected from the group consisting of:
Asn, Arg, Lys, Orn, Trp, Tyr, Phe, His,
R5 represents an L or D-amino acid residue selected from the group consisting of:
Ala, Trp, Tyr, Phe, His,
R6 represents an L or D-amino acid residue selected from the group consisting of:
Ala, Trp, Tyr, Phe, His, and
Y represents —OH, amide, methylamide, or ethylamide groups.

12 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/314,795Filed 7 May 2021 · continuation in part
Priority: 8 May 2019
Published: US 2021/0107940 A19 Sep 2021
Granted: 27 Jun 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07K 7/06
Linear peptides containing only normal peptide links: having 5 to 11 amino acids
A61P 35/00
Antineoplastic agents
C07K 5/1024
Tetrapeptides: with the first amino acid being heterocyclic
A61K 38/00
Medicinal preparations containing peptides

Family

Application62/845,156Us provisional application · filed 8 May 2019
Application16/870,253Parent of this continuation-in-part · filed 8 May 2020
US 2021/0277060 A1Pre-grant publication · published 9 Sep 2021
US 11,518,784 B2Parent of this continuation-in-part
US 2021/0107940 A1Published application
US 11,685,766 B2This patent

From the US filing history. Foreign family members aren’t listed.